• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regenxbio Inc (NQ: RGNX )

8.608 -0.232 (-2.63%)
Streaming Delayed Price Updated: 2:52 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regenxbio Inc

< Previous 1 2 3 4 5 Next >
What 4 Analyst Ratings Have To Say About Regenxbio
October 10, 2024
Via Benzinga
Assessing Regenxbio: Insights From 5 Financial Analysts
September 04, 2024
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
Where Regenxbio Stands With Analysts
August 05, 2024
Via Benzinga
Assessing Regenxbio: Insights From 4 Financial Analysts
June 07, 2024
Via Benzinga
Evaluating Regenxbio: Insights From 9 Financial Analysts
May 15, 2024
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
From FN Media Group LLC
Via GlobeNewswire
Why Is Clearside Biomedical Stock Gaining Today?
June 25, 2024
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
Via Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Where Regenxbio Stands With Analysts
April 12, 2024
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
March 06, 2024
Via Benzinga
Regenxbio: Q4 Earnings Insights
February 27, 2024
Via Benzinga
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
June 21, 2024
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. 
Via Benzinga
Exposures Product Safety
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
June 20, 2024
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
Via Investor's Business Daily
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
June 13, 2024
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
Via Investor's Business Daily
Exposures Product Safety
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
A Preview Of Regenxbio's Earnings
February 26, 2024
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
March 25, 2024
Via Benzinga
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
March 13, 2024
The threat is still emerging, but it could be significant. 
Via The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
March 08, 2024
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
March 05, 2024
Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 05, 2024
Via Benzinga
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 01, 2024
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
Via Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
February 12, 2024
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
The One-Minute Market Report - Sunday, Feb. 11
February 11, 2024
In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments... 
Via Talk Markets
Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
February 08, 2024
Jim Cramer, the host of CNBC's "Mad Money," has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap